UK 19:05 Friday, 23 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Warning: perhaps it is best not to play this podcast in front of the kids. On the agenda today I remember when Evil Knievil was a 3Dimmer - good investors accept that facts change, I note this in reference to MX Oil (MXO). I also discuss the folly of leaping to conclusions with reference to Falanx (FLX) and cover DQ Entertainment (DQE) and why Nomads are so skittish these days. Then it is on to Imaginatik (IMTK) and my old sparring partner the fraudster Rob Terry before I end up with a discussion of spraying ones todger and what to make of the situation at Plethora (PLE), the baby of my old friend Jim Mellon
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments
Duck and Dive
Futura (FUM) hasn’t exactly thrilled with its todger lotion (which they are now reduced to flogging directly to the flaccid few who can find its website) so I don’t see why PLE should succeed.
And don’t get me started on pussies.
James
Fortacin does not have FDA approval as you say, I wish it had! It has EMA approval to be delivered in a 20 dose cannister. The cannister is now undergoing stability testing in order to support an EMA variation approval to be delivered in a 6 dose (reduced fill) cannister, as this is considered commercially advantageous. It is this delay which has caused all the problems for Ple, but it is a delay only.
The valuation of Ple for RP was produced by Grant Sherman and the valuation was $194,891,000, so whilst you make take that with a pinch of salt or see it as a shield against lawsuits one could also argue that RP are getting Ple on the cheap.
Ple has a £6 million milestone payment on tap from Recordati once the variation approval is obtained (begin 3rd qtr 2016) and it has two further licence agreements on tap conditional upon the variation approval- these will be smaller.
The strategic decision to transform RP into a bio pharma company was taken some time ago and no doubt Ple figured in that decision as it was first mentioned a long time ago within its website.
The short term loan will be cleared as an intercompany balance upon completion of the takeover, it is an expedient, sensible and the cheapest way to deal with a short term cash flow sitaution – we have all had those.The the cash within RP will allow Ple to continue with its FDA submission (the main use for those funds) together with milestone receipts from the other licensees.
This is a marriage between a company with cash and no product and a company with a potential blockbuster treatment and no cash. To characterise it as a rescue of a bust company is somewhat harsh in my view. RP has already bought out the Sharwood Royalties for £2.8 m, so all future RP shareholders will benefit from that. PLe has valuable tax losses and of course the Cayman domicile of RP may present further tax advantages.
The share price has been crushed due to the workings of the AIM market, the irrationality of most AIM investors who are lazy and probably don’t even know what Ple does and as you say the HK listing issue.
Baker Brothers did sell down some of their holding, but this seems to have halted – that might even of just been part of a larger asset allocation exercise within their portfolio to move into higher cash holdings given the current bio-pharma outlook.
Hope this helps.
SDH
Why spend a fortune on ‘Premaway’ when a few pints of lager will do the trick nicely?
bwakem
There is already a drug you can take for prem-ejac called Priligy. Taking a single pill sounds a lot more convenient than spraying your todger.
Shaz
Hi Tom,
The following article provides a unique insight into PE sufferers http://www.vice.com/read/the-men-who-use-antidepressants-to-last-longer-in-bed